Banka Bioloo Limited (banka) FY26: Earnings Recovered, FY27: Cash Conversion Focus

Banka BioLoo Limited (BANKA) has announced its financial results for FY26, showing a recovery in earnings. The company reported a total income of ₹58.4 crore, marking a 7.1% increase from the previous year. The EBITDA for the year stood at ₹6.49 crore, a significant improvement from the negative EBITDA of ₹2.55 crore in FY25. Excluding other income, the PAT was ₹5.20 crore, up from a loss of ₹8.91 crore in FY25. The focus for FY27 is on converting the contracted revenues into cash, aiming for sustainable profitability and recurring revenue streams.

FY26 Performance Overview

The financial recovery in FY26 was driven by execution discipline, procurement efficiency, and selective growth. The company’s order book stands at ₹107 crore, with ₹70 crore identified for the next 12 months. The Megaliter platform, which funds, owns, and contracts, continues to play a crucial role in the company’s strategy. The LTV (Lifetime Value) portfolio indicator stands at ₹122 crore, with 16 contracted projects and an operational portfolio of ₹14.1 crores.

Future Focus: FY27 Cash Conversion

For FY27, Banka BioLoo Limited aims to convert the contracted revenues into cash through improved billing, collections, and working-capital discipline. The company plans to move work-in-progress projects into service, improve collections, and strengthen profitability. The goal is to convert the platform into recurring earnings and cash, ensuring sustainable growth and profitability.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Banka BioLoo Limited

Banka BioLoo Limited belongs to the Industrials › Pollution & Treatment Controls sector. Here’s a quick read on where the business and the stock stand today.

Banka falls 10.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 1.6% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 10.5% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Banka BioLoo Limited.